Uncategorized Archives - Page 2 of 151

WednesdayMar 11, 2026 11:15 am

Earth Science Tech Inc. (ETST) Is Operating a Diversified Portfolio of Businesses in the Pharmaceutical, Healthcare, Telemedicine and Consumer Markets

Earth Science Tech is a holding company that acquires and manages businesses in several markets, emphasizing execution, capital discipline, and long-term value creation across the company’s various platforms. The company generally focuses on controlling interests in companies where disciplined scaling, regulatory compliance, and operational oversight can drive growth. The team at Earth Science Tech is led by executives with years of experience in areas like finance, business, real estate, digital infrastructure, and others. Earth Science Tech (OTC: ETST), a strategic holding company, operates a portfolio in the pharmaceutical, telemedicine, healthcare and consumer markets. The company strives to build value by…

WednesdayMar 11, 2026 10:30 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Appoints TMS, Neuroplasticity Researcher Joshua Brown MD, PhD, as Chief Medical Innovation Officer

Prof. Brown is a leading researcher in Transcranial Magnetic Stimulation (“TMS”) and currently serves as President of the Clinical TMS Society. His work explores how brain stimulation therapies can be enhanced through neuroplasticity-focused medications, including D-cycloserine, a component of NRx’s investigational drug NRX‑101. Brown previously received funding from the Defense Advanced Research Projects Agency (“DARPA”) to study treatments for military personnel suffering from Post-Traumatic Stress Disorder (“PTSD”). NRx is investigating a treatment approach combining ketamine, TMS, and hyperbaric oxygen in patients with PTSD and depression, with trials planned through its HOPE Therapeutics clinic network. The appointment reflects NRx’s evolving strategy…

TuesdayMar 10, 2026 10:00 am

New Research Challenges Current Thinking on How Brain Cancer Develops

South Korean scientists have published the results of a study that provides vital insights indicating that brain cancer develops much earlier than the time when tumors become visible. Their findings could alter how brain cancer treatment is approached, especially efforts geared at limiting the possibility of its recurrence. The study focused on IDH-mutant glioma, a type of brain cancer that is most common among brain cancer patients who haven’t reached the age of 50. This cancer is difficult to treat due to its high likelihood of regrowth after a patient has undergone therapy. Current treatment approaches focus on the surgical…

MondayMar 09, 2026 12:00 pm

Building a New Cancer Care Ecosystem: Liora’s Proton Therapy and LIXTE’s Drug Pipeline in Synergy

LIXTE Biotechnology Holdings and the company’s subsidiary, Liora Technologies, both develop products that aim to improve outcomes for cancer patients Specifically, Liora’s Linac for Image Guided Hadron Therapy (“LiGHT”) System and LIXTE’s LB-100 work together to fight cancer As a result, the companies are building a new cancer care ecosystem that hopes to boost the effectiveness of treatments, while also help them be more accessible for a wider range of patients Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy. Specifically,…

MondayMar 09, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Secures Key European Milestone for Dusquetide Development

“The EMA's positive opinion signifies an important step for Soligenix as we continue to advance the program,” says company CEO. The designation provides incentives that may include protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval. Dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body’s innate immune system rather than suppress it outright. For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the European Medicines Agency (EMA) not only validates a…

MondayMar 09, 2026 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Moves Forward Focused on Advancing Portable, High-Fidelity Cardiac Monitoring

The company’s core innovation, the HeartBeam System, is positioned as the first cable-free, high-fidelity ECG system capable of capturing the heart’s electrical signals from three distinct directions. HeartBeam’s strategy is built around addressing a long-standing gap in cardiac care. Looking forward, HeartBeam is focused on advancing both its hardware and software platforms. HeartBeam (NASDAQ: BEAT) stands at a pivotal point in its development as a medical technology company focused on transforming how cardiac arrhythmias are detected, evaluated and monitored. Headquartered in Santa Clara, California, HeartBeam is building a platform designed starting with its FDA-cleared synthesized 12-lead ECG system to bring…

FridayMar 06, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

The promise of immunotherapy lies in its ability to harness the body’s own immune defenses to recognize and destroy malignant cells LB-100, the lead compound developed by LIXTE Biotechnology, is part of this emerging wave of tumor-sensitizing agents The company is advancing LB-100 through clinical development in collaboration with academic and research institutions Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology’s most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as PD-1 and PD-L1 inhibitors and CAR-T cell therapies can fail in tumors that remain immunologically “cold” or invisible to…

ThursdayMar 05, 2026 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach

Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages. Soligenix’s development of synthetic hypericin illustrates this “one drug, multiple diseases” model in action. HyBryte is being developed to treat both cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin, and psoriasis. Modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. Rather than building entirely new molecules for every indication, companies are developing platform technologies that allow a single therapeutic approach to be adapted across conditions. Soligenix…

WednesdayMar 04, 2026 9:45 am

Scaling Care, Tightening Controls: How Earth Science Tech Inc. (ETST) Is Building a Multi-Unit Healthcare Platform

Earth Science Tech reported fiscal Q3 2026 revenue of $8.4 million, up 14.1% year over year, with gross margin expanding to 76.3% and adjusted EBITDA rising to $1.2 million Management said Peaks, the company’s telemedicine platform, surpassed $2.0 million in revenue in less than a year, while the company pursues additional state licenses to expand its footprint ETST engaged Semple, Marchal and Cooper, LLP as its independent PCAOB auditor, a governance move framed as necessary as consolidated accounting complexity increases Healthcare delivery is being reshaped by two forces that often move at different speeds: consumer demand for faster access and…

TuesdayMar 03, 2026 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target on Commercialization Momentum

New report upgrades HeartBeam to buy, raises 12-month price target to $4, citing regulatory progress and company’s transition toward commercialization. Joseph Gunnar characterized the FDA clearance of HeartBeam’s 12-lead ECG synthesis software for arrhythmia assessment as a “critical regulatory milestone.” The research report underscores the company’s targeted go-to-market strategy. Equity research reports often serve as important barometers of shifting sentiment, offering investors detailed analysis of a company’s strategy, risks and growth potential. In a new research note, Joseph Gunnar & Co. upgraded HeartBeam (NASDAQ: BEAT) from Hold to Buy and raised its 12-month price target to $4 from $1, citing…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Earth Science Tech Inc. (ETST) Is Operating a Diversified Portfolio of Businesses in the Pharmaceutical, Healthcare, Telemedicine and Consumer Markets

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Appoints TMS, Neuroplasticity Researcher Joshua Brown MD, PhD, as Chief Medical Innovation Officer

New Research Challenges Current Thinking on How Brain Cancer Develops

Building a New Cancer Care Ecosystem: Liora’s Proton Therapy and LIXTE’s Drug Pipeline in Synergy

Soligenix Inc. (NASDAQ: SNGX) Secures Key European Milestone for Dusquetide Development

HeartBeam Inc. (NASDAQ: BEAT) Moves Forward Focused on Advancing Portable, High-Fidelity Cardiac Monitoring

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research

Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach

Scaling Care, Tightening Controls: How Earth Science Tech Inc. (ETST) Is Building a Multi-Unit Healthcare Platform

HeartBeam Inc. (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target on Commercialization Momentum

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search